RR Donnelley (RRD) Acquired by Chatham for $10.85/sh Cash

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/22/2026

1. SPCX
2. NVDA
3. ACN
4. USO
5. APGE
6. DFTX
7. GOOGL
8. MU
9. HOOD
10. IBM

Go back to RR Donnelley (RRD) Acquired by Chatham for $10.85/sh Cash

RR Donnelley (RRD) Board Views Chatham's Unsolicited $10.85/Share Proposal as 'Superior Proposal'

December 10, 2021 4:41 PM EST

R.R. Donnelley & Sons Company (NYSE: RRD) announced today that its Board of Directors (the Board) unanimously determined that an unsolicited proposal from Chatham Asset Management, LLC (Chatham) to acquire all of the common stock of the Company not already owned by Chatham and its affiliates for $10.85 per share in cash (the Revised Chatham Proposal) constitutes a Superior Proposal as defined in the Companys previously announced definitive merger agreement with affiliates of Atlas Holdings LLC (Atlas), dated as of November 3, 2021 (as amended on December 9, 2021, the Amended Agreement), subject to the condition that Chatham agree to extend the Revised... More

Pre-Open Stock Movers 12/10: (CNTX) (AI) (ORCL) Higher; (ANGN) (CCNC) (MRNA) Lower (more...)

December 10, 2021 9:26 AM EST

Pre-Open Stock Movers

Vifor Pharma and Angion Biomedica Corp. (NASDAQ: ANGN) 22.6% LOWER; announced results from the exploratory phase-II GUARD trial of Angions ANG-3777 in patients undergoing cardiac surgery involving cardiopulmonary bypass at risk for developing acute kidney injury (CSA-AKI). The trial did not meet its primary endpoint of percentage increase in serum creatinine based upon the area under the curve (AUC). However, Angion and Vifor Pharma continue to review the data, based on the signal demonstrated in the clinically-relevant MAKE90 secondary endpoint.

Context Therapeutics Inc. (Nasdaq:... More